Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.

doi:10.1016/j.jtho.2018.07.016

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2018

Su Shan, Dong Zhong-Yi, Xie Zhi, Yan Li-Xu, Li Yu-Fa, Su Jian, Liu Si-Yang, Yin Kai, Chen Rui-Lian, Huang Shu-Mei, Chen Zhi-Hong, Yang Jin-Ji, Tu Hai-Yan, Zhou Qing, Zhong Wen-Zhao, Zhang Xu-Chao, Wu Yi-Long

Abstract excerpt

INTRODUCTION: This study evaluated whether tumor expression of programmed death ligand 1 (PD-L1) could predict the response of EGFR-mutated NSCLC to EGFR tyrosine kinase inhibitor (TKI) therapy. METHODS: We retrospectively evaluated patients who received EGFR-TKIs for advanced NSCLC at the Guangdong Lung Cancer Institute between April 2016 and September 2017 and were not enrolled in clinical studies. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Programmed Cell Death 1 Receptor

Share to Protein Kinase Inhibitors

Share to Survival Analysis

Source

Open in PubMed

Identifiers

PMID: 30056164
DOI: 10.1016/j.jtho.2018.07.016

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.PMID 30056164Read ↗

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.Semantic proximity Read ↗

Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs.Semantic proximity Read ↗

The new idea of cancer immunotherapy: the expression of PD-L1 may reveal the immunological mechanism of resistance of EGFR-TKIsSemantic proximity Read ↗

[Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation].Semantic proximity Read ↗

Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.Semantic proximity Read ↗

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancerSemantic proximity Read ↗

Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).Semantic proximity Read ↗

Strong programmed cell death ligand-1 affect clinical outcomes in advanced non-small cell lung cancer treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitorsSemantic proximity Read ↗

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.Semantic proximity Read ↗

[A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.